Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NWBO has made additional information available on their website in the “Investors & Media” section.
https://www.nwbio.com
Thoughts and prayers on their way to you.
It appears I missed a grand Birthday Party taking place somewhere within the last 1,000 posts.
Happy Birthday Sentiment and Evaluate!
Novocure’s press release today re Glioblastoma
https://www.firstwordpharma.com/node/1523281?tsid=28®ion_id=4
Great wrap-up.....
In addition to new job postings for Cognate BioServices, I’m sure you are watching “Leadership” names on the Cognate website and most likely noticed the removal of the VP of Quality Assurance, Regulatory Affairs, Tim Mitchell. Mr. Mitchell may have moved on to another company or, as I surmise, he was reassigned to Sawston to oversee startup activities at that location. Note the commendable experience in manufacturing operations Mr. Mitchell brought to Cognate’s table when he joined them in December 2016.
https://www.linkedin.com/in/tim-mitchell-06259564
Disclosure: Breadcrumb trails have come to amuse me in the current cone of silence.
Because some NWBO MB posters have recently cited Dr. Cobb’s reference to aspirin effectiveness with cancer patients, I am sure this article will further validate his statement:
https://www.firstwordpharma.com/node/1514130?tsid=28®ion_id=5
That was news on the international level, on the domestic front:
https://www.firstwordpharma.com/node/1513166?tsid=28®ion_id=2
Comments appreciated.
Regarding the EMA, here’s a perplexing read with your morning coffee:
https://www.firstwordpharma.com/node/1510645?tsid=28®ion_id=2
The notice that NWBO will not be presenting has now been placed on the SMI Conference website:
NWBO remains listed as a Sponsor and was recently joined by a second Sponsor: TCRS (Tailored Clinical Research Solutions) a London based CRO: Does NWBO have a working relationship with TCRS at hospital sites?
https://www.smi-online.co.uk/pharmaceuticals/uk/cancer-vaccines?utm_medium=www.cancervaccinesevent.com&utm_source=P-221&utm_campaign=ihub#tab_sponsors
Noticed: NWBO was the only sponsor of SMI conference - there has been an addition since the cancellation announcement:
TAILORED CLINICAL RESEARCH SOLUTIONS
Sponsors and Exhibitors
http://www.tcr-solutions.com/
Tailored Clinical Research Solutions (www.tcr-solutions.com) recognise that Cancer Vaccine studies are among the most complex projects that a CRO will undertake. We know this because we are experts in oncology clinical development. That is why we will never ask a CRA with less than 7 years experience to work on your study. And why we ensure that our sponsors work with the very best oncology sites from our tried and tested global network. Whether you are seeking full support for your clinical development programme or just for one part of a study, TCRS offers flexibility, momentum and value.
About Tailored Clinical Research Solutions
TCRS is led by a team with an exceptionally detailed knowledge of the UK’s clinical research sector.
Our employees provide expertise in the legislative perspective, a detailed understanding of research governance, Good Clinical Practice and experience of managing trials in the NHS, commercial and academic environments.
Have these SEC filings been posted today?
https://www.sec.gov/cgi-bin/browse-edgar?company=Northwest+Biotherapeutics&owner=exclude&action=getcompany
Your professional insight and comment is acknowledged!
DMB…As NWBO approaches the start of a combo clinical trial, your post indicates to me that you would be interested in reading the following:
Recent interview with Dr. Balazs Flink, Head of Clinical Trial Analysis, BMY
R&D Strategy; External Partnerships; AI; etc.
http://www.bigdataleadersforum.com/knowledge-centre/interviews/interview-with-balazs-fink?platform=hootsuite
Dr. Flink will be speaking at the upcoming Data on Precision Medicine on Wednesday, Nov. 1, 2017
Integrating clinical trial analytics solutions under one centralized organization to drive enterprise level decision-making through data
psgd
Wishes for comfort and healing light being sent your way.
Duly noted with thanks!
I admit I’m getting lost in a maze of scientific jargon, regulatory hell, and bullies of frightening size.
Thank you Doc Logic for scrutinizing the report and isolating items of interest for NWBO supporters on this board. The link in my post brought interested parties to TrakCel, a COP (cell orchestration platform) company mentioned in a previous post.
Your expertise and attentiveness to small details, often times hidden, are impressive.
Sorry for your sadness, Eagle. My deepest sympathies.
Know when to “fold them”
White flag
Checkmate
Most of us are aware that LP is on the agenda to speak at the Cancer Vaccines Conference in London on September 27th. In reviewing the conference’s website, I was curious as to some of the verbiage in the “overview” of the conference on the site - the last sentence in the quoted paragraph that follows:
“With focal points of the conference including autologous tumour cell immunotherapy, combinatorial approaches (including immune checkpoint inhibitors and IDO inhibitors) and case studies of current clinical trials, this conference will provide the perfect platform to highlight emerging strategies in cancer vaccines. The conference will also aim to provide solutions to circumvent the challenges which face the development of successful targeted cancer treatments, within a competitive and important market.”
https://www.smi-online.co.uk/pharmaceuticals/uk/cancer-vaccines?utm_medium=www.cancervaccinesevent.com&utm_source=P-221&utm_campaign=ihub#tab_overview
Also noted: NWBO is the only sponsor for this conference.
“If (as many here claim) NWBO is doing exactly what AZN did, why not do it right? Why not redesign the trial and re-allocate the alpha? Why the secrecy?”
Your post duly noted:
AZN is a powerful brand; they have earned their status and respect, they can approach and address issues with credibility and confidence - not so with NWBO, the possible disruptor in an arena of giants. NWBO enjoys no such recognition. Their corporate behavior parallels the reality of their position at this time. As we are all witnessing, their strategy seems to be “keep your heads low and fly under the radar” until………
IMO of course.
Hey, Good Morning Eagle
Well, let’s see what this interesting day brings to the table.